Nrx reports remarks by israel institute for biological research on the future of the brilife™ covid-19 investigational vaccine

Radnor, pa., feb. 11, 2022 (globe newswire) -- nrx pharmaceuticals (nasdaq: nrxp), a clinical-stage, biopharmaceutical company, today reported remarks by dr. shmuel yitzhaki, director of the israel institute for biological research, who spoke at the eli hurvitz institute for strategic management of tel aviv university. his remarks were summarized in the hebrew language edition of globes as follows:
NRXP Ratings Summary
NRXP Quant Ranking